JP6898848B2 - 脳転移を治療するための方法 - Google Patents

脳転移を治療するための方法 Download PDF

Info

Publication number
JP6898848B2
JP6898848B2 JP2017515756A JP2017515756A JP6898848B2 JP 6898848 B2 JP6898848 B2 JP 6898848B2 JP 2017515756 A JP2017515756 A JP 2017515756A JP 2017515756 A JP2017515756 A JP 2017515756A JP 6898848 B2 JP6898848 B2 JP 6898848B2
Authority
JP
Japan
Prior art keywords
inhibitor
cancer
subject
gap junction
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017515756A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017534583A5 (OSRAM
JP2017534583A (ja
Inventor
ジョアン マッサーグ，
ジョアン マッサーグ，
エイドリアン ボワール，
エイドリアン ボワール，
チン チェン，
チン チェン，
Original Assignee
メモリアル スローン ケタリング キャンサー センター
メモリアル スローン ケタリング キャンサー センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター, メモリアル スローン ケタリング キャンサー センター filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2017534583A publication Critical patent/JP2017534583A/ja
Publication of JP2017534583A5 publication Critical patent/JP2017534583A5/ja
Application granted granted Critical
Publication of JP6898848B2 publication Critical patent/JP6898848B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
JP2017515756A 2014-09-19 2015-09-18 脳転移を治療するための方法 Active JP6898848B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052966P 2014-09-19 2014-09-19
US62/052,966 2014-09-19
PCT/US2015/051057 WO2016044790A1 (en) 2014-09-19 2015-09-18 Methods for treating brain metastasis

Publications (3)

Publication Number Publication Date
JP2017534583A JP2017534583A (ja) 2017-11-24
JP2017534583A5 JP2017534583A5 (OSRAM) 2018-10-25
JP6898848B2 true JP6898848B2 (ja) 2021-07-07

Family

ID=55533931

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017515756A Active JP6898848B2 (ja) 2014-09-19 2015-09-18 脳転移を治療するための方法

Country Status (7)

Country Link
US (3) US10413522B2 (OSRAM)
EP (2) EP3685832B1 (OSRAM)
JP (1) JP6898848B2 (OSRAM)
CN (1) CN107106544B (OSRAM)
AU (3) AU2015317330B2 (OSRAM)
CA (1) CA2961894C (OSRAM)
WO (1) WO2016044790A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044790A1 (en) * 2014-09-19 2016-03-24 Memorial Sloan-Kettering Cancer Center Methods for treating brain metastasis
CN107290438B (zh) * 2016-03-31 2020-10-16 深圳翰宇药业股份有限公司 一种多肽有关物质的高效液相色谱分析方法
BR112020000477A2 (pt) * 2017-07-10 2020-07-21 Cornell University ataque à instabilidade cromossômica e sinalização de dna citosólico a jusante para tratamento de câncer
KR102901842B1 (ko) * 2017-08-11 2025-12-19 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 암 전이의 치료를 위한 키나제의 표적화
US11717506B2 (en) 2019-05-07 2023-08-08 The Johns Hopkins University Neuroprotective compounds for amyotrophic lateral sclerosis
WO2021051015A1 (en) * 2019-09-13 2021-03-18 Auckland Uniservices Limited Compositions and methods for rescuing retinal and choroidal structure and function
CN111420025B (zh) * 2020-04-28 2021-06-11 中国药科大学 茜草科类型环肽化合物在制备cGAS-STING信号通路激活剂的药物中的应用
GB202014831D0 (en) 2020-09-21 2020-11-04 Dc Europa Ltd Disconnection agents
US12306192B2 (en) * 2021-02-08 2025-05-20 Cedars-Sinai Medical Center Method of detecting cognitive impairment
CA3242726A1 (en) * 2021-12-14 2023-06-22 Trustees Of Tufts College Use of hyperpolarizing agents alone and in combination with other therapeutic agents for treating cancers including glioblastoma
CN114252324B (zh) * 2022-03-02 2022-05-13 中国人民解放军军事科学院军事医学研究院 一种方便使用的多孔脑片孵育装置
US20260034158A1 (en) * 2022-07-20 2026-02-05 The University Of North Carolina At Chapel Hill Methods of treating cancer of the central nervous system comprising 5-ethynyl-2'-deoxyuridine
WO2025024284A1 (en) * 2023-07-21 2025-01-30 The Board Of Regents Of The University Of Texas System Monoclonal antibodies against pcdh7 for lung cancer therapy
CN117298143A (zh) * 2023-10-11 2023-12-29 广州医科大学附属第一医院（广州呼吸中心） β葡聚糖在制备治疗肺癌脑转移瘤药物中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0764159B1 (en) 1994-06-10 2000-08-09 Smithkline Beecham Plc C -4 amide substituted compounds and their use as therapeutic agents
GB9411635D0 (en) 1994-06-10 1994-08-03 Smithkline Beecham Plc Novel treatment
AU740588B2 (en) 1997-11-24 2001-11-08 Scripps Research Institute, The Inhibitors of gap junction communication
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6251931B1 (en) 1998-11-24 2001-06-26 The Scripps Research Institute Inhibitors of gap junction communication
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
US6770633B1 (en) 1999-10-26 2004-08-03 Immusol, Inc. Ribozyme therapy for the treatment of proliferative skin and eye diseases
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
WO2001068836A2 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
JP4331115B2 (ja) 2002-11-29 2009-09-16 独立行政法人科学技術振興機構 コネキシン２６阻害剤および癌転移抑制剤
WO2005011708A1 (en) * 2003-07-31 2005-02-10 The Board Of Regents Of The University Of Texas System Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers
EP2662088A3 (en) 2005-02-03 2014-02-19 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
WO2008127251A1 (en) 2006-05-05 2008-10-23 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Reversible inhibition of pyramidal gap junction activity
AU2008343755A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides and peptides for the treatment ofabnormal or excessive scars
US20130281524A1 (en) * 2008-06-05 2013-10-24 Peter Blower Novel treatments
KR101496508B1 (ko) * 2008-08-27 2015-03-03 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 독성을 감소시키고 질환을 치료하거나 예방하기 위한 화합물, 조성물과 방법
FR2935611B1 (fr) * 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
WO2011057199A1 (en) * 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
JP2013512887A (ja) * 2009-12-03 2013-04-18 プロキシマゲン リミテッド 感染症の治療
AU2010325755A1 (en) 2009-12-03 2012-06-21 Proximagen Ltd Treatment of infectious diseases
WO2014129914A1 (en) * 2013-02-22 2014-08-28 Auckland Uniservices Limited Methods of treatment
ES2982836T3 (es) * 2013-04-29 2024-10-17 Memorial Sloan Kettering Cancer Center Composiciones y métodos para alterar la señalización de segundos mensajeros
EP3057977A4 (en) * 2013-10-15 2017-07-26 President and Fellows of Harvard College Methods and compositions for eradicating leukemic cells
WO2016044790A1 (en) * 2014-09-19 2016-03-24 Memorial Sloan-Kettering Cancer Center Methods for treating brain metastasis

Also Published As

Publication number Publication date
WO2016044790A1 (en) 2016-03-24
US11058665B2 (en) 2021-07-13
NZ730319A (en) 2024-03-22
US20170258758A1 (en) 2017-09-14
EP3685832B1 (en) 2023-08-30
AU2015317330B2 (en) 2021-01-14
US12029717B2 (en) 2024-07-09
EP3193865A1 (en) 2017-07-26
AU2021202257A1 (en) 2021-05-06
US10413522B2 (en) 2019-09-17
CN107106544B (zh) 2021-09-24
CA2961894A1 (en) 2016-03-24
CN107106544A (zh) 2017-08-29
AU2021202257B2 (en) 2023-05-25
CA2961894C (en) 2023-12-12
JP2017534583A (ja) 2017-11-24
AU2023219864A1 (en) 2023-09-14
EP3193865A4 (en) 2018-04-11
AU2015317330A1 (en) 2017-04-13
US20220105069A1 (en) 2022-04-07
EP3193865B1 (en) 2019-11-06
US20200085781A1 (en) 2020-03-19
EP3685832A1 (en) 2020-07-29

Similar Documents

Publication Publication Date Title
AU2021202257B2 (en) Methods for treating brain metastasis
Fan et al. TSPAN8+ myofibroblastic cancer–associated fibroblasts promote chemoresistance in patients with breast cancer
Caporali et al. miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A
Jia et al. MiR-7-5p suppresses stemness and enhances temozolomide sensitivity of drug-resistant glioblastoma cells by targeting Yin Yang 1
Chen et al. Carcinoma–astrocyte gap junctions promote brain metastasis by cGAMP transfer
Sieve et al. A positive feedback loop between IL-1β, LPS and NEU1 may promote atherosclerosis by enhancing a pro-inflammatory state in monocytes and macrophages
Cai et al. MicroRNA-374a activates Wnt/β-catenin signaling to promote breast cancer metastasis
Liang et al. miR-27a-3p targeting RXRα promotes colorectal cancer progression by activating Wnt/β-catenin pathway
Wang et al. Tumor-derived EV-encapsulated miR-181b-5p induces angiogenesis to foster tumorigenesis and metastasis of ESCC
Wu et al. circFBXO7/miR-96-5p/MTSS1 axis is an important regulator in the Wnt signaling pathway in ovarian cancer
Xu et al. RETRACTED: The novel role of circular RNA ST3GAL6 on blocking gastric cancer malignant behaviours through autophagy regulated by the FOXP2/MET/mTOR axis
Zhong et al. Ubiquitin-specific protease 15 contributes to gastric cancer progression by regulating the Wnt/β-catenin signaling pathway
Subramani et al. The brain microenvironment negatively regulates miRNA-768-3p to promote K-ras expression and lung cancer metastasis
Feng et al. Rab27A mediated by NF-κB promotes the stemness of colon cancer cells via up-regulation of cytokine secretion
CN103648505B (zh) 与微rna-21、错配修复和结肠直肠癌相关的材料和方法
Sheng et al. Exosomal miRNA-92a derived from cancer-associated fibroblasts promote invasion and metastasis in breast cancer by regulating G3BP2
Yang et al. Extracellular vesicle‐packaged miR‐181c‐5p from epithelial ovarian cancer cells promotes M2 polarization of tumor‐associated macrophages via the KAT2B/HOXA10 axis
Chen et al. SNORA73B promotes endometrial cancer progression through targeting MIB1 and regulating host gene RCC1 alternative splicing
Tang et al. Circ-100290 positively regulates angiogenesis induced by conditioned medium of human amnion-derived mesenchymal stem cells through miR-449a/eNOS and miR-449a/VEGFA axes
Yin et al. Ubiquitin-specific peptidase 15 regulates the TFAP4/PCGF1 axis facilitating liver metastasis of colorectal cancer and cell stemness
Huang et al. lncRNA-WAL promotes triple-negative breast cancer aggression by inducing β-catenin nuclear translocation
Taylor et al. Y-box binding protein-1: A neglected target in pediatric brain tumors?
Ren et al. Fucosyltransferase 8‐Derived Circular RNA Drives M2 Polarization of Macrophages Through ENO1‐TNF Signaling Axis to Promote Lung Cancer Progression
Sun et al. circTOP2A functions as a ceRNA to promote glioma progression by upregulating RPN2
Ma et al. The HNRNPC/CELF2 signaling pathway drives glycolytic reprogramming and mitochondrial dysfunction in drug-resistant acute myeloid leukemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201229

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210402

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210520

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210611

R150 Certificate of patent or registration of utility model

Ref document number: 6898848

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250